News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
About Mesothelioma
Latest News
- Cancer Surgeons form Band to Benefit Cancer Resear...
- Progress in War on Cancer
- Wife Vows to Continue to Fight for Mesothelioma Cu...
- Earlier Detection of Mesothelioma Possible from Te...
- LIVESTRONG Brings Countries Together for Fight Aga...
- Mesothelioma Victim Raises Awareness
- Photographer Uses Art to Get the Word Out on Mesot...
- New Test for Early Diagnosis of Mesothelioma
- Clinical Trials Key to Mesothelioma Treatment Brea...
- Father Upset Over Lack of Government Control of As...
News Archives
- April 2007
- May 2007
- June 2007
- July 2007
- August 2007
- September 2007
- October 2007
- November 2007
- December 2007
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
- June 2008
- July 2008
- August 2008
- September 2008
- October 2008
- November 2008
- December 2008
- January 2009
- February 2009
- March 2009
- April 2009
- May 2009
- June 2009
- July 2009
- August 2009
- September 2009
- October 2009
- November 2009
Monday, September 14, 2009
Researchers are seeking 40 patients that have confirmed malignant mesothelioma, who are not candidates for surgery or radiation, to test the drug gefitinib. Gefitinib inhibits cellular growth in cancerous cells by targeting the proteins. The trade name for gefitinib is Iressa.Malignant mesothelioma is a cancer caused by exposure to airborne asbestos fibers. The fibers are either inhaled or swallowed then travel through the body becoming lodged, resulting in cancer decades later. Often called “asbestos cancer,” mesothelioma is resistant to many current treatments. Currently there is no known cure for mesothelioma, and the average survival time varies from 4 - 18 months after diagnosis.
The study, conducted by researchers at the National Cancer Institute in Bethesda, Maryland, is a Phase II clinical trial to determine the efficacy of the drug for mesothelioma patients. Currently, the drug is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), and who have previously been treated with chemotherapy.
Patients involved in the study will receive daily doses of oral gefitinib while being monitored. Clinicians will follow study participants for up to four years.
Gefitinib Clinical Trial
Labels: ClinicalTrial, mesothelioma, treatments
posted by Nancy Meredith at 1:00 PM
